Cited by 192Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrovascular and genetic disorders

White Matter Hyperintensities and Cerebral Amyloidosis: Necessary and Sufficient for Clinical Expression of Alzheimer Disease?

Open access
Provenzano, Frank A., Muraskin, Jordan, Tosto, Giuseppe, Narkhede, Atul, Wasserman, Ben T., Griffith, Erica Y., Guzman, Vanessa A., Meier, Irene B. +3 more·2013·JAMA Neurology

Abstract

IMPORTANCE: Current hypothetical models emphasize the importance of β-amyloid in Alzheimer disease (AD) pathogenesis, although amyloid alone is not sufficient to account for the dementia syndrome. The impact of small-vessel cerebrovascular disease, visualized as white matter hyperintensities (WMHs) on magnetic resonance imaging scans, may be a key factor that contributes independently to AD presentation. OBJECTIVE: To determine the impact of WMHs and Pittsburgh Compound B (PIB) positron-emission tomography-derived amyloid positivity on the clinical expression of AD. DESIGN: Baseline PIB-positron-emission tomography values were downloaded from the Alzheimer's Disease Neuroimaging Initiative database. Total WMH volume was derived on accompanying structural magnetic resonance imaging data. We examined whether PIB positivity and total WMHs predicted diagnostic classification of patients with AD (n = 20) and control subjects (n = 21). A second analysis determined whether WMHs discriminated between those with and without the clinical diagnosis of AD among those who were classified as PIB positive (n = 28). A third analysis examined whether WMHs, in addition to PIB status, could be used to predict future risk for AD among subjects with mild cognitive impairment (n = 59). SETTING: The Alzheimer's Disease Neuroimaging Initiative public database. PARTICIPANTS: The study involved data from 21 normal control subjects, 59 subjects with mild cognitive impairment, and 20 participants with clinically defined AD from the Alzheimer Disease's Neuroimaging Initiative database. MAIN OUTCOME MEASURES: Clinical AD diagnosis and WMH volume. RESULTS: Pittsburgh Compound B positivity and increased total WMH volume independently predicted AD diagnosis. Among PIB-positive subjects, those diagnosed as having AD had greater WMH volume than normal control subjects. Among subjects with mild cognitive impairment, both WMH and PIB status at baseline conferred risk for future diagnosis of AD. CONCLUSIONS AND RELEVANCE: White matter hyperintensities contribute to the presentation of AD and, in the context of significant amyloid deposition, may provide a second hit necessary for the clinical manifestation of the disease. As risk factors for the development of WMHs are modifiable, these findings suggest intervention and prevention strategies for the clinical syndrome of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2013.1321

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 53 · Cited by 192

Research works printed but not linked: 1

  1. [34]Admiraal-Behloul F Olofesen H Van den Heuvel DM Schmitz N Reiber JH Van Buchem MA Fully automated lobe delineation for regional white matter lesion load quantification in a large scale study Proceedings International Society for Magnetic Resonance in medicine 2004 138

Authors
Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., Guzman, V. A., Meier, I. B., Zimmerman, M. E., Brickman, A. M., & Alzheimer's Disease Neuroimaging Initiative, F. T.
Affiliations
  • Columbia University Irving Medical Center (US)
  • Columbia University (US)
  • Albert Einstein College of Medicine (US)
Corresponding author
Brickman, Adam M.
Venue
JAMA Neurology
Published
2013-04-01
Volume
70
Issue
4
Pages
455
ISSN
2168-6149 (ISSN-L)
OpenAlex
W2128581044
Cited by
192
References
53
Citations by year
2026: 2 · 2025: 8 · 2024: 7 · 2023: 8 · 2022: 17 · 2021: 7 · 2020: 10 · 2019: 21 · 2018: 20 · 2017: 19 · 2016: 11 · 2015: 26 · 2014: 20 · 2013: 16
FWCI
17.24
Type
journal article
Language
en
Open access
Locations
  • JAMA Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Alzheimer's Association (AG029949, AG034189, AG010129, U01 AG024904)
  • Bristol-Myers Squibb (U01 AG024904, AG024904)
  • Eli Lilly and Company (U01 AG024904, AG024904)
  • Pfizer (AG024904, U01 AG024904)
  • AstraZeneca
  • Biogen (U01 AG024904, AG024904)
  • F. Hoffmann-La Roche (AG024904, U01 AG024904)
  • Medpace (U01 AG024904)
  • Meso Scale Diagnostics (U01 AG024904, AG024904)
  • Synarc (U01 AG024904, P30 AG010129, K01 AG030514)
  • Alzheimer's Disease Neuroimaging Initiative (U01AG024904, AG024904, P30 AG010129, K01 AG030514)
  • Amorfix Life Sciences
  • BioClinica (U01 AG024904, AG024904)
  • Novartis Pharmaceuticals Corporation (U01 AG024904, AG024904)
  • Northern California Institute for Research and Education (U01 AG024904, K01 AG030514, P30 AG010129)
  • Bayer HealthCare
  • Eisai (U01 AG024904, AG024904)
  • Servier (AG024904, U01 AG024904)
  • IXICO (AG024904, U01 AG024904)
  • National Institutes of Health (3u01ag024904-10s2, U01-AG024904, AG010129, AG024904, AG034189)
  • Genentech (AG024904, U01 AG024904)
  • University of California, Los Angeles
  • University of California, San Diego
  • Canadian Institutes of Health Research (U01 AG024904, K01 AG030514, P30 AG010129)
  • National Institute on Aging (U01-AG-024904, P30AG010129, R56AG034189, K01AG030514, AG029949, R01AG034189, AG034189, K23AG029949, U19AG010483)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Cerebrovascular and genetic disorders
Keywords
white matter hyperintensities, cerebral amyloidosis, Alzheimer's disease, Pittsburgh compound B, amyloid PET, cerebral small vessel disease, mild cognitive impairment, Alzheimer's disease risk prediction, Alzheimer's Disease Neuroimaging Initiative
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Amyloidosis, Aniline Compounds, Brain Mapping, Cerebral Cortex, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Nerve Fibers, Myelinated, Thiazoles, Databases, Factual, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review